Price and reimbursement of medicines when new indications are approved: the results of a survey on ISPOR Italy Rome Chapter members
DOI:
https://doi.org/10.33393/grhta.2023.2562Keywords:
Indication, Italy, Medicines, PricingAbstract
Multi-indication pricing models for medicines and some international impact evidence are available in the literature. Data on the Italian context are more limited. This paper illustrates the results of a study aimed at gathering the opinion on this topic of experts, members of the ISPOR Italy Rome Chapter.
The opinion was collected through a structured questionnaire, validated by two potential responders, and administered online in the period October/July 2022.
There were 45 responders (20% of the members); 67% of responders work in pharmaceutical companies and 13% in consultancy firms. The remainder belongs to regulators/payers and universities.
The survey highlighted a preference for (i) non-automatic models, as automatic approaches are mainly based on price cuts/discount increases in relation to an increase in volumes, (ii) an “indication-based-pricing” model (where prices are differentiated by indication through discounts/risk sharing agreements), since it is more consistent with a value-based approach, even if more complex to manage, (iii) a mix of discounts/agreements according to existing evidence.
The opinion collected is consistent with the opinions available in the literature, but not consistent with the Italian trend, where, compared to the past, a blended approach is prevailing. A blended pricing envisages a renegotiation of the single price for all indications, essentially based on a change in the discount. Our hope is that in the future the experts’ opinion will be taken into consideration and that a targeted indication-based-pricing will be adopted again.
Downloads
References
Preckler V, Espín J. The Role of Indication-Based Pricing in Future Pricing and Reimbursement Policies: A Systematic Review. Value Health. 2022;25(4):666-675. https://doi.org/10.1016/j.jval.2021.11.1376 PMID:35227598 DOI: https://doi.org/10.1016/j.jval.2021.11.1376
Campillo-Artero C, Puig-Junoy J, Segú-Tolsa JL, Trapero-Bertran M. Price Models for Multi-indication Drugs: A Systematic Review. Appl Health Econ Health Policy. 2020;18(1):47-56. https://doi.org/10.1007/s40258-019-00517-z PMID:31523756 DOI: https://doi.org/10.1007/s40258-019-00517-z
Cole A, Neri M, Cookson G. Payment Models for Multi-Indication Therapies. Online https://www.ohe.org/publications/payment-models-multi-indication-therapies. (Accessed July 2022). DOI: https://doi.org/10.1016/j.jval.2021.11.680
Antonanzas F, Juárez-Castelló C, Lorente R, Rodríguez-Ibeas R. The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments. PharmacoEconomics. 2019;37(12):1469-1483. https://doi.org/10.1007/s40273-019-00838-w PMID:31535280 DOI: https://doi.org/10.1007/s40273-019-00838-w
Whittal A, Jommi C, De Pouvourville G, et al. Facilitating More Efficient Negotiations for Innovative Therapies: A Value-Based Negotiation Framework - Corrigendum. Int J Technol Assess Health Care. 2022;38(1):e43. https://doi.org/10.1017/S0266462322000290PMID:35607832 DOI: https://doi.org/10.1017/S0266462322000290
Xoxi E, Rumi F, Kanavos P, et al. A Proposal for Value-Based Managed Entry Agreements in an Environment of Technological Change and Economic Challenge for Publicly Funded Healthcare Systems. Front Med Technol. 2022;4:888404. https://doi.org/10.3389/fmedt.2022.888404 PMID:35782579 DOI: https://doi.org/10.3389/fmedt.2022.888404
Riccaboni M, Swoboda T, Van Dyck W. Pharmaceutical net price transparency across european markets: insights from a multi-agent simulation model. Health Policy. 2022;126(6):534-540. https://doi.org/10.1016/j.healthpol.2022.03.013 PMID:35459584 DOI: https://doi.org/10.1016/j.healthpol.2022.03.013
Michaeli DT, Mills M, Kanavos P. Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland. Appl Health Econ Health Policy. 2022;20(5):757-768. https://doi.org/10.1007/s40258-022-00737-w PMID:35821360 DOI: https://doi.org/10.1007/s40258-022-00737-w
Pani L, Cicchetti A, De Luca A, et al. Pricing for multi-indication medicines: a discussion with Italian experts. Pharmadvance 2022; 4 (2): 163-170. Online http://www.pharmadvances.com/pricing-for-multi-indication-medicines-a-discussion-with-italian-experts/. (Accessed July 2022). DOI: https://doi.org/10.36118/pharmadvances.2022.27
Additional Files
Published
How to Cite
License
Copyright (c) 2023 The authors
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Accepted 2023-04-25
Published 2023-05-02
